Robert C Gadwood

This inventor holds 34 USPTO granted patents and 9 published patent applications, plus 4 CIPO patents and 4 EPO patents, primarily in Oxazolidinone Compounds. Top assignees: Pharmacia & Upjohn Company, Exithera Pharmaceuticals, Inc., Metabolic Solutions Development Company, LLC. Active years: 1995-2024.

USPTO Granted Patents = 34 (Patent Applications = 9)

% Patents Active = 67.6

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 2.9

ph-index = 8

Forward Citations = 163(Granted Patents)

Location History:

Kalamazoo, MI (US) (1995 - 2011)
Portage, MI (US) (2002 - 2024)

Company Filing History:

17 out of 523

Pharmacia & Upjohn Company

patents

5 out of 6

Exithera Pharmaceuticals, Inc.

patents

5 out of 11

Metabolic Solutions Development Company, LLC

patents

4. 3 out of 48

G1 Therapeutics, Inc.

Years Active: 1995-2024

Loading Chart...

Areas of Expertise:

Therapeutic Compounds

Oxazolidinone

Thiazolidinedione

Pyrimidine-Based

Antiproliferative

HSPC-Sparing

Modified Creatine

Acyloxymethylcarbamate

Photoaffinity Probes

Aminoaryl N-Oxides

Bicyclic Antibacterials

Spirocyclic Imidazolines

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084414 - Therapeutic compounds and compositions (2024-09-10),

2. 11198673 - Therapeutic compounds and compositions (2021-12-14),

3. 10654831 - Antiproliferative pyrimidine-based compounds (2020-05-19),

4. 10376519 - Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation (2019-08-13),

5. 10259785 - Therapeutic compounds and compositions (2019-04-16),

6. 9994521 - Therapeutic compounds and compositions (2018-06-12),

7. 9717735 - Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation (2017-08-01),

8. 9499532 - Therapeutic compounds and compositions (2016-11-22),

9. 9434753 - Modified creatine compounds (2016-09-06),

10. 8946435 - Synthesis for thiazolidinedione compounds (2015-02-03),

11. 8933240 - Synthesis for thiazolidinedione compounds (2015-01-13),

12. 8895748 - Synthesis for thiazolidinedione compounds (2014-11-25),

13. 8304441 - Thiazolidinedione analogues for the treatment of metabolic diseases (2012-11-06),

14. 8067450 - Thiazolidinedione analogues for the treatment of metabolic diseases (2011-11-29),

15. 7265140 - Acyloxymethylcarbamate prodrugs of oxazolidinones (2007-09-04),

Title: Spotlight on Robert C. Gadwood: Innovations in Therapeutics

Introduction: Robert C. Gadwood, an accomplished inventor based in Portage, MI, has made significant contributions to the field of therapeutic compounds. With an impressive portfolio of 34 patents, his work has been pivotal in developing innovative solutions that impact healthcare.

Latest Patents: Among Robert's recent patents are his groundbreaking inventions related to therapeutic compounds and compositions. These inventions focus on compounds that inhibit Factor XIa or kallikrein, along with methods for utilizing these compounds and compositions effectively. This advancement has the potential to transform treatment protocols in various medical scenarios.

Career Highlights: Throughout his career, Robert has been associated with notable companies such as Pharmacia & Upjohn Company and Metabolic Solutions Development Company, LLC. His roles in these organizations have allowed him to explore and expand his expertise in pharmaceutical innovations, enhancing healthcare through scientific advancements.

Collaborations: Robert has collaborated with esteemed professionals in the field, including Lisa Marie Thomasco and Bharat V. Kamdar. Their teamwork has fostered a productive environment that has led to substantial progress in their shared goals of enhancing therapeutic interventions.

Conclusion: Robert C. Gadwood stands out in the landscape of inventors with his impressive array of patents and his commitment to innovation in the therapeutic realm. Through his work and collaborations, he continues to make impactful contributions that resonate within the medical community and beyond.